{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T06:26:23Z","timestamp":1792045583560,"version":"4.4.0"},"reference-count":47,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,2,2]],"date-time":"2021-02-02T00:00:00Z","timestamp":1612224000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008551","name":"Fondation M\u00e9rieux","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008551","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Tuberculosis (TB) is a leading infectious cause of death. To improve treatment efficacy, quicker monitoring methods are needed. The objective of this study was to monitor the response to a heparin-binding hemagglutinin (HBHA) interferon-<jats:italic>\u03b3<\/jats:italic> (IFN-<jats:italic>\u03b3<\/jats:italic>) release assay (IGRA) and QuantiFERON-TB Gold Plus (QFT-P) and to analyze plasma IFN-<jats:italic>\u03b3<\/jats:italic> levels according to sputum culture conversion and immune cell counts during treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This multicentered cohort study was based in Bangladesh, Georgia, Lebanon, Madagascar, and Paraguay. Adult, non-immunocompromised patients with culture-confirmed pulmonary TB were included. Patients were followed up at baseline (T0), after two months of treatment (T1), and at the end of therapy (T2). Clinical data and blood samples were collected at each timepoint. Whole blood samples were stimulated with QFT-P antigens or recombinant methylated <jats:italic>Mycobacterium tuberculosis<\/jats:italic> HBHA (produced in <jats:italic>Mycobacterium smegmatis;<\/jats:italic> rmsHBHA). Plasma IFN-<jats:italic>\u03b3<\/jats:italic> levels were then assessed by ELISA.<\/jats:p><\/jats:sec><jats:sec><jats:title>Findings<\/jats:title><jats:p>Between December 2017 and September 2020, 132 participants completed treatment, including 28 (21.2%) drug-resistant patients. rmsHBHA IFN-<jats:italic>\u03b3<\/jats:italic> increased significantly throughout treatment (0.086 IU\/ml at T0 <jats:italic>vs<\/jats:italic>. 1.03 IU\/ml at T2, p &amp;lt; 0.001) while QFT-P IFN-<jats:italic>\u03b3<\/jats:italic> remained constant (TB1: 0.53 IU\/ml at T0 <jats:italic>vs<\/jats:italic>. 0.63 IU\/ml at T2, p = 0.13). Patients with low lymphocyte percentages (&amp;lt;14%) or high neutrophil percentages (&amp;gt;79%) at baseline had significantly lower IFN-<jats:italic>\u03b3<\/jats:italic> responses to QFT-P and rmsHBHA at T0 and T1. In a small group of slow converters (patients with positive cultures at T1; n = 16), we observed a consistent clinical pattern at baseline (high neutrophil percentages, low lymphocyte percentages and BMI, low TB1, TB2, and MIT IFN-<jats:italic>\u03b3<\/jats:italic> responses) and low rmsHBHA IFN-<jats:italic>\u03b3<\/jats:italic> at T1 and T2. However, the accuracy of the QFT-P and rmsHBHA IGRAs compared to culture throughout treatment was low (40 and 65% respectively). Combining both tests improved their sensitivity and accuracy (70\u201380%) but not their specificity (&amp;lt;30%).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>We showed that QFT-P and rmsHBHA IFN-<jats:italic>\u03b3<\/jats:italic> responses were associated with rates of sputum culture conversion. Our results support a growing body of evidence suggesting that rmsHBHA IFN-<jats:italic>\u03b3<\/jats:italic> discriminates between the different stages of TB, from active disease to controlled infection. However, further work is needed to confirm the specificity of QFT-P and rmsHBHA IGRAs for treatment monitoring.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2020.616450","type":"journal-article","created":{"date-parts":[[2021,2,2]],"date-time":"2021-02-02T21:42:23Z","timestamp":1612302143000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":40,"title":["Relevance of QuantiFERON-TB Gold Plus and Heparin-Binding Hemagglutinin Interferon-\u03b3 Release Assays for Monitoring of Pulmonary Tuberculosis Clearance: A Multicentered Study"],"prefix":"10.3389","volume":"11","author":[{"given":"Carole","family":"Chedid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eka","family":"Kokhreidze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nestani","family":"Tukvadze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayera","family":"Banu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Khaja Mafij","family":"Uddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samanta","family":"Biswas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graciela","family":"Russomando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chyntia Carolina D\u00edaz","family":"Acosta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossana","family":"Arenas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulo PR.","family":"Ranaivomanana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Crisca","family":"Razafimahatratra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Perlinot","family":"Herindrainy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio","family":"Rakotonirina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antso Hasina","family":"Raherinandrasana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niaina","family":"Rakotosamimanana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monzer","family":"Hamze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad Bachar","family":"Ismail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rim","family":"Bayaa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Luc","family":"Berland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavio","family":"De Maio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Delogu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hubert","family":"Endtz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Ader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delia","family":"Goletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,2,2]]},"reference":[{"key":"B1","volume-title":"Global tuberculosis report 2020","year":"2020"},{"key":"B2","volume-title":"Guidelines for treatment of drug-susceptible tuberculosis and patient care","year":"2017"},{"key":"B3","volume-title":"WHO consolidated guidelines on drug-resistant tuberculosis treatment","year":"2019"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12889-017-4188-9","article-title":"The prevalence and factors associated for anti-tuberculosis treatment non-adherence among pulmonary tuberculosis patients in public health care facilities in South Ethiopia: a cross-sectional study","volume":"17","author":"Woimo","year":"2017","journal-title":"BMC Public Health"},{"key":"B5","doi-asserted-by":"publisher","first-page":"e238","DOI":"10.1371\/journal.pmed.0040238","article-title":"Patient Adherence to Tuberculosis Treatment: A Systematic Review of Qualitative Research","volume":"4","author":"Munro","year":"2007","journal-title":"PLoS Med"},{"key":"B6","volume-title":"Global Tuberculosis Report 2018","year":"2018"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(10)70071-2","article-title":"Sputum monitoring during tuberculosis treatment for predicting outcome : systematic review and meta-analysis","volume":"10","author":"Horne","year":"2010","journal-title":"Lancet Infect Dis"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.02451-10","article-title":"Role of the clinical mycobacteriology laboratory in diagnosis and management of tuberculosis in low-prevalence settings","volume":"49","author":"Parrish","year":"2011","journal-title":"J Clin Microbiol"},{"key":"B9","volume-title":"Early detection of Tuberculosis : an overview of approaches, guidelines and tool","year":"2011"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1801089","DOI":"10.1183\/13993003.01089-2018","article-title":"Can we predict tuberculosis cure? Current tools available","volume":"52","author":"Goletti","year":"2018","journal-title":"Eur Respir J"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/s41564-019-0380-2","article-title":"A sytematic review of biomarkers to detect active tuberculosis","volume":"4","author":"MacLean","year":"2019","journal-title":"Nat Microbiol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/resp.13272","article-title":"Update on tuberculosis biomarkers: From correlates of risk, to correlates of active disease and of cure from disease","volume":"23","author":"Goletti","year":"2018","journal-title":"Respirology"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.16.0880","article-title":"Interferon-gamma response to the treatment of active pulmonary and extra-pulmonary tuberculosis","volume":"21","author":"Liang","year":"2017","journal-title":"Int J Tuberc Lung Dis"},{"key":"B14","doi-asserted-by":"publisher","first-page":"236","DOI":"10.20944\/preprints201701.0035.v1","article-title":"Use of the QuantiFERON-TB Gold In-Tube Test in the Diagnosis and Monitoring of Treatment Efficacy in Active Pulmonary Tuberculosis","volume":"14","author":"Chang","year":"2017","journal-title":"Int J Environ Res Public Health"},{"key":"B15","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41598-018-33825-w","article-title":"Effect of therapy on Quantiferon-Plus response in patients with active and latent tuberculosis infection","volume":"8","author":"Petruccioli","year":"2018","journal-title":"Sci Rep"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01976-2016","article-title":"QuantiFERON-TB Gold Plus as a potential tuberculosis treatment monitoring tool","volume":"49","author":"Kamada","year":"2017","journal-title":"Eur Respir J"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2334-8-11","article-title":"Response to M. tuberculosis selected RD1 peptides in Ugandan HIV-infected patients with smear positive pulmonary tuberculosis: A pilot study","volume":"8","author":"Goletti","year":"2008","journal-title":"BMC Infect Dis"},{"key":"B18","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/1471-2334-11-135","article-title":"IP-10 response to RD1 antigens might be a useful biomarker for monitoring tuberculosis therapy","volume":"11","author":"Kabeer","year":"2011","journal-title":"BMC Infect Dis"},{"key":"B19","doi-asserted-by":"publisher","first-page":"e00664","DOI":"10.1128\/JCM.00664-18","article-title":"Depressed Gamma Interferon Responses and Treatment Outcomes in Tuberculosis Patients: a Prospective Cohort Study","volume":"56","author":"Feng","year":"2018","journal-title":"J Clin Microbiol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.02278-12","article-title":"Gamma Interferon Release Assay for Monitoring of Treatment Response for Active Tuberculosis : an Explosion in the Spaghetti Factory","volume":"51","author":"Denkinger","year":"2013","journal-title":"J Clin Microbiol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1080\/23744235.2017.1279747","article-title":"The role of Quantiferon-TB Gold in-Tube in the diagnosis and treatment monitoring of active tuberculosis The role of Quantiferon-TB Gold in-Tube in the diagnosis and treatment monitoring of active tuberculosis","volume":"49","author":"Bartalesi","year":"2017","journal-title":"Infect Dis (Auckl)"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.tube.2015.07.002","article-title":"Interferon gamma release assays for monitoring the response to treatment for tuberculosis : A systematic review","volume":"95","author":"Clifford","year":"2015","journal-title":"Tuberculosis"},{"key":"B23","doi-asserted-by":"publisher","first-page":"e18315","DOI":"10.1371\/journal.pone.0018315","article-title":"Methylated HBHA produced in M. smegmatis discriminates between active and non-active tuberculosis disease among RD1-responders","volume":"6","author":"Delogu","year":"2011","journal-title":"PLoS One"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.tube.2006.01.016","article-title":"Heparin-binding hemagglutinin, from an extrapulmonary dissemination factor to a powerful diagnostic and protective antigen against tuberculosis","volume":"86","author":"Locht","year":"2006","journal-title":"Tuberculosis"},{"key":"B25","doi-asserted-by":"publisher","first-page":"e926","DOI":"10.1371\/journal.pone.0000926","article-title":"Heparin-binding-hemagglutinin-induced IFN-\u03b3 release as a diagnostic tool for latent tuberculosis","volume":"2","author":"Hougardy","year":"2007","journal-title":"PLoS One"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0043285","article-title":"Risk stratification of latent tuberculosis defined by combined interferon gamma release assays","volume":"7","author":"Corbi\u00e8re","year":"2012","journal-title":"PLoS One"},{"key":"B27","doi-asserted-by":"publisher","first-page":"101966","DOI":"10.1016\/j.tube.2020.101966","article-title":"QuantiFERON-TB Gold Plus combined with HBHA-Induced IFN-\u03b3 release assay improves the accuracy of identifying tuberculosis disease status","volume":"124","author":"Tang","year":"2020","journal-title":"Tuberculosis"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2018.09.011","article-title":"Combined use of Quantiferon and HBHA-based IGRA supports tuberculosis diagnosis and therapy management in children","volume":"77","author":"Sali","year":"2018","journal-title":"J Infect"},{"key":"B29","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.ijid.2020.09.017","article-title":"Association of baseline white blood cell counts with tuberculosis treatment outcome: a prospective multicentered cohort study","author":"Chedid","year":"2020","journal-title":"Int J Infect Dis"},{"key":"B30","volume-title":"Global Tuberculosis Report 2019","year":"2019"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.cegh.2012.11.002","article-title":"Enhancing research capacities in infectious diseases: The GABRIEL network, a joint approach to major local health issues in developing countries","volume":"1","author":"Komurian-Pradel","year":"2013","journal-title":"Clin Epidemiol Glob Heal"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-017-2948-1","article-title":"Involvement of methylated HBHA expressed from Mycobacterium smegmatis in an IFN-\u03b3 release assay to aid discrimination between latent infection and active tuberculosis in BCG-vaccinated populations","volume":"36","author":"Wen","year":"2017","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"B33","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/1471-2288-13-100","article-title":"Selecting a sample size for studies with repeated measures","volume":"13","author":"Guo","year":"2013","journal-title":"BMC Med Res Methodol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.14.0100","article-title":"Successful \u20189-month Bangladesh regimen\u2019 for multidrugresistant tuberculosis among over 500 consecutive patients","volume":"18","author":"Aung","year":"2014","journal-title":"Int J Tuberc Lung Dis"},{"key":"B35","first-page":"1101062","article-title":"QuantiFERON\u00ae-TB Gold Plus (QFT\u00ae-Plus) Package Insert","volume":"96","year":"2013"},{"key":"B36","article-title":"Castor Electronic Data Capture [online]","author":"Castor","year":"2019"},{"key":"B37","doi-asserted-by":"publisher","first-page":"152","DOI":"10.5395\/rde.2017.42.2.152","article-title":"Statistical notes for clinical researchers: Chi-squared test and Fisher\u2019s exact test","volume":"42","author":"Kim","year":"2017","journal-title":"Restor Dent Endod"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1080\/00401706.1964.10490181","article-title":"Multiple Comparisons Using Rank Sums","volume":"6","author":"Dunn","year":"1964","journal-title":"Technometrics"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1590\/0074-02760140316","article-title":"Clinical and epidemiological profiles of individuals with drug-resistant tuberculosis","volume":"110","author":"Pedro","year":"2015","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.74.5.3006-3011.2006","article-title":"The hbhA gene of Mycobacterium tuberculosis is specifically upregulated in the lungs but not in the spleens of aerogenically infected mice","volume":"74","author":"Delogu","year":"2006","journal-title":"Infect Immun"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fcimb.2017.00033","article-title":"Heparin-binding hemagglutinin of Mycobacterium tuberculosis is an inhibitor of autophagy","volume":"7","author":"Zheng","year":"2017","journal-title":"Front Cell Infect Microbiol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200701-084OC","article-title":"Regulatory T cells depress immune responses to protective antigens in active tuberculosis","volume":"176","author":"Hougardy","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.201606-482OC","article-title":"IFN-\u03b3 release assay result is associated with disease site and death in active tuberculosis","volume":"13","author":"Auld","year":"2016","journal-title":"Ann Am Thorac Soc"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1086\/511277","article-title":"Immunosuppression during Active Tuberculosis Is Characterized by Decreased Interferon-y Production and CD25 Expression with Elevated Forkhead Box P3 , Transforming Growth Factor \u2013 b , and Interleukin-4 mRNA Levels","volume":"195","author":"Roberts","year":"2007","journal-title":"J Infect Dis"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1086\/507427","article-title":"Region of Difference 1 Antigen\u2013Specific CD4 + Memory T Cells Correlate with a Favorable Outcome of Tuberculosis","volume":"194","author":"Goletti","year":"2006","journal-title":"J Infect Dis"},{"key":"B46","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1111\/imr.12274","article-title":"T cells and adaptive immunity to Mycobacterium tuberculosis in humans","volume":"264","author":"Jasenosky","year":"2015","journal-title":"Immunol Rev"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwu140","article-title":"Correcting for optimistic prediction in small data sets","volume":"180","author":"Smith","year":"2014","journal-title":"Am J Epidemiol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2020.616450\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,2]],"date-time":"2021-02-02T21:42:28Z","timestamp":1612302148000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2020.616450\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,2]]},"references-count":47,"alternative-id":["10.3389\/fimmu.2020.616450"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2020.616450","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,2]]},"article-number":"616450"}}